Recently, we identified Insulinoma-Glucagonoma clone 20 (IG20) that can render cells more susceptible to tumor necrosis factor-alpha (TNF-a)-induced apoptosis. In addition, it can slow cell proliferation, and enhance drugand radiation-induced cell death. TNF-related apoptosisinducing ligand (TRAIL) can selectively induce apoptosis in some cancer cells and render others susceptible to cotreatment with drugs and irradiation, with little or no effect on most normal cells. In this study, we investigated the potential of IG20 to enhance TRAIL-induced apoptosis and found that it can render cells more susceptible to TRAIL treatment through enhanced activation of caspases. Further, we showed that this effect can be suppressed by caspase inhibitors, p35 and CrmA, and a dominant-negative Fas-associated death domaincontaining protein (DN-FADD) . Results from colocalization and immunoprecipitation studies showed that IG20 can interact with TRAIL death receptors (DR), DR4 and DR5 and increase recruitment of FADD and caspase-8 into the TRAIL death-inducing signaling complex (DISC). These results indicate that IG20 is a novel protein that can enhance TRAIL-induced apoptosis by facilitating DISC formation.
Introduction
The IG-20 gene is overexpressed in human tumors and cancer cell lines, and can encode four different splice variants namely, IG20, MADD, IG20-SV2 and DENN-SV (Goto et al., 1992; Chow and Lee, 1996; Cunningham, 1996; Schievella et al., 1997; Chow et al., 1998; Al-Zoubi et al., 2001) . These splice variants are expressed in different permutations and combinations in all tissues and cell lines tested to date. The DENN-SV splice variant is constitutively expressed in all cells and tissues, and is highly expressed in human tumors and cancer cell lines relative to normal tissues, and other splice variants. Moreover, cells transfected with a cDNA encoding DENN-SV proliferate more aggressively, form larger colonies in soft agar and become resistant to TNF-a, gamma-irradiation, etoposide and vinblastine treatments. In contrast, cells transfected with a cDNA encoding IG20 splice variant grow slowly in culture and become more susceptible to cell death induced by the above treatments. The other two splice variants, MADD and IG20-SV2, exhibit little or no effect on these properties (Efimova et al., 2004) .
Reduced proliferation of IG20-transfected cells appears to be largely due to cell-cycle arrest (Efimova et al., 2003) . Although the splice variants differ in their ability to affect cell proliferation and apoptosis, they all can interact with the TNFR1 upon TNF-a treatment and enhance TNF-a-induced mitogen activated protein (MAP) kinase, and extracellular signal regulated (ERK) kinase activities (Schievella et al., 1997; AlZoubi et al., 2001) . However, only HeLa cells transfected with IG20 splice variant can enhance activation of caspase-8 and -3 that could be blocked by CrmA (AlZoubi et al., 2001) . From these and other results, we concluded that IG20 acts as a proapoptotic molecule in enhancing TNF-a-induced apoptosis.
The TNF-related apoptosis-inducing ligand (TRAIL) is a unique member of the TNF superfamily (Wiley et al., 1995) that can kill cancer cells selectively with little or no effect on most normal cells (Jo et al., 2000; Leverkus et al., 2000) . Upon TRAIL treatment, similar to TNF-a-and CD95L-induced signaling, FADD and caspase-8 are recruited to the DR4 and DR5 death inducing signaling complexes (DISC) (Bodmer et al., 2000; Kischkel et al., 2000; Sprick et al., 2000) .
Thus, TRAIL-, TNF-a-and CD95L-induced apoptotic signaling pathways share some common features. Therefore, in this study, we tested the effects of IG20 on TRAIL-induced signaling.
Our results showed that IG20 can enhance TRAILinduced apoptosis in HeLa cells through increased activation of caspases. The underlying mechanism appears to involve IG20 interaction with both DR4 and DR5 and increased FADD and caspase-8 recruitment to the DISC leading to activation of caspases-8 and -3. From these results, we conclude that IG20 can potentiate TRAIL-induced apoptosis most likely by facilitating DISC formation.
Results

HeLa cells transfected stably with IG20 show enhanced susceptibility to TRAIL-induced apoptosis
We determined the degree of TRAIL-induced apoptosis using several different approaches, which included activation of caspases, mitochondrial depolarization and chromatin condensation. HeLa cells stably transfected with either IG20 or a control vector were treated with TRAIL for 5 h. Earlier studies from our laboratory have shown that this duration of treatment is optimal for analysis of all three different cell death markers (AlZoubi et al., 2001) . As indicated in Figure 1a , HeLa IG20 cells showed increased total caspase activation as determined by the binding of the broad-spectrum caspase inhibitor, Z-VAD conjugated to FITC, increased mitochondrial depolarization as detected by the dye TMRE ( Figure 1b ) and higher percentage of cells that were positive for Hoechst staining indicating chromatin condensation (Figure 1c) . Consistent with our earlier findings (Al-Zoubi et al., 2001) , a similar increase in apoptosis of IG20 cells upon treatment with TNF-a and cycloheximide was observed. There was, however, approximately 3-3.5-fold increase in cells undergoing apoptosis after TRAIL treatment relative to only a twofold increase after TNF-a treatment. Our results demonstrated that IG20 can enhance TRAIL-induced apoptosis to a higher magnitude relative to the enhancement seen after TNF-a and cycloheximide treatment.
Control and IG20 stably transfected cells display similar surface expression of TRAIL receptors
Differential susceptibility of normal primary cell lines versus transformed cell lines to TRAIL was initially attributed to the presence of at least one decoy receptor 
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M Ramaswamy et al in normal cells, but its absence in tumor cell lines. The DcR1 and DcR2 decoy receptors attenuate TRAILinduced signaling by competing for the ligand binding to DR4 and DR5 (Degli-Esposti et al., 1997; Pan et al., 1997 Pan et al., , 1998 . Therefore, the relative levels of expression of different TRAIL receptors could profoundly affect the ability of TRAIL to induce apoptosis. To rule out the possibility that IG20 may affect the levels of expression of these receptors, we analysed for their surface expression. As seen in Figure 2a , the levels of expression of all four receptors were comparable in both control and HeLa IG20 cells, indicating that stable expression of IG20 had no significant effect on the surface expression of various TRAIL receptors.
Endogenous transcription of TRAIL and TNFR1 are not altered in HeLa IG20 cells TRAIL is expressed in a variety of normal tissues as well as in tumor cell lines (Wiley et al., 1995) , and transcriptional upregulation of TRAIL induced due to different factors can result in increased apoptosis of cells . In order to test whether IG20 enhanced apoptosis through upregulation of TRAIL, we subjected poly A þ mRNA from HeLa IG20 and control cells to reverse transcription-polymerase chain reaction (RT-PCR). Our previous (Al- Zoubi et al., 2001) and current results showed that IG20 can enhance TNF-a-induced apoptosis and, therefore, we also tested for upregulation of TNFR1 in HeLa IG20 cells. Results in Figure 2b indicate that HeLa cells stably transfected with IG20 did not show any increase in the levels of either TRAIL or TNFR1 expression.
Receptor stability in IG20 HeLa cells
It has been previously shown that a delay in the death receptor turnover could accentuate sensitivity of HeLa cells to TRAIL-induced apoptosis (Neznanov et al., 2002) . In order to test the possibility that HeLa IG20 cells might have a slower rate of receptor turnover than the controls, cells were treated with brefeldin A, which blocks Golgi function and prevents receptor replenishment on the cell surface. Treatment of both HeLa IG20 and control cells with brefeldin A showed no difference in the stability of DR5 on the cell surface ( Figure 2c) either at 3 or 6 h, indicating that differences in the rate of receptor turnover was not responsible for the enhanced apoptosis of HeLa IG20 cells.
HeLa IG20 cells show increased activation of initiator and effector caspases
Addition of TRAIL results in receptor clustering, which facilitates FADD and caspase-8 recruitment leading to effector caspase-3 activation (Bodmer et al., Kischkel et al., 2000; Sprick et al., 2000) . In order to analyse whether IG20 mediated its effects by increasing activation of caspases, we tested for levels of caspase-8, which is the main activator caspase involved in TRAIL-mediated death pathway. Caspase-10, a molecule with sequence similarity to caspase-8 has been shown to participate with caspase-8 in the DR4 and DR5 signaling pathways (Kischkel et al., 2001; Sprick et al., 2002) , and therefore we determined their levels in TRAIL-treated cells. As seen in Figure 3a , the IG20 enhances TRAIL-induced apoptosis M Ramaswamy et al levels of both caspases, measured in fluorescence intensity, increased in TRAIL-treated HeLa IG20 cells compared to TRAIL-treated control cells. To ensure validity of these observations, we tested for apoptosis using three different concentrations of TRAIL. As indicated, enhanced levels of caspase activation was noted with cells treated with 25 ng/ml showing continued increase in caspase activity up to 6 h, while at higher concentrations, the maximal levels were reached by 3 h. It is interesting to note that there was maximal activation of caspase-8 and -9 even in the lowest concentration of TRAIL (Figure 3b ). Cleavage of procaspase-8 results in active caspase-8 and a 10 kDa fragment (p10) that can be readily detected in a Western blot using a p10-specific antibody. An increase in the amount of cleaved caspase-8 is seen in HeLa IG20 cells relative to the control cells tested at different time points after TRAIL treatment (Figure 3c ). The blot was probed with anti-b-actin to ensure equal protein loading.
Activated caspase-8 could cleave cytoplasmic Bid, which can subsequently translocate to the mitochondria leading to activation of the mitochondrial pathway and caspase-9 (Suliman et al., 2001; Yamada et al., 1999 ). Therefore, we tested for caspase-9 activation. Consistent with the results obtained from TMRE staining (Figure 1b) , activation of caspase-9 was increased in HeLa IG20 cells relative to control cells (Figure 3a) .
Caspase-3, the main downstream effector caspase, is activated either directly by active caspase-8, or indirectly through Bid cleavage leading to the activation of mitochondrial pathway and caspase-9. The levels of active caspase-3 in HeLa IG20 as well as control cells were measured by staining treated cells with a specific antiactive caspase-3 phycoerythrin (PE)-conjugated antibody. As seen in Figure 3d , IG20 HeLa cells showed considerably higher levels of caspase-3 activation relative to control cells. The relative increase in caspase-3 activation was more profound in TRAILtreated HeLa IG20 cells relative to control cells (fivefold increase), when compared to cells treated with TNF-a (less than twofold increase). To further validate these results, we treated cells with different doses of TRAIL for different durations. Time-and dose-dependent responses were apparent ( Figure 3e ) with maximal caspase activation at 3 h in IG20-transfected cells (75%) treated with the two higher concentrations of TRAIL, relative to 45% in vector-transfected control cells.
These results show that IG20 can promote activation of caspase-8 and -10 on one hand and caspase-9 on the other, perhaps both contributing to the activation of caspase-3 and enhanced apoptosis.
TRAIL-induced apoptosis can be inhibited by caspase inhibitors and DN-FADD
Our results showed increased activation of caspases in HeLa IG20 cells relative to control cells after TRAIL treatment. In order to further confirm the necessity of different caspases for enhanced apoptosis in HeLa IG20 cells, and to begin to identify the potential site of action of IG20 in the signaling pathway, we used caspase inhibitors, p35, a baculovirus-derived general caspase inhibitor and CrmA, a poxvirus protein that can inhibit caspase-8 and -1 preferentially. Both p35 and CrmA abrogated TRAIL-induced apoptosis in both control as well as IG20 cells (Figure 4 ). FADD is an essential upstream adaptor molecule that is required for the recruitment of casapase-8 in TRAIL-induced apoptosis (Kuang et al., 2000) . Therefore, we assessed the levels of active caspase-3 as a marker of apoptosis in control and HeLa IG20 cells transfected with a DN-FADD and found that these cells were almost completely resistant At 24 h post-transfection, TRAIL was added at a concentration of 100 ng/ml for 5 h, and both treated and untreated cells were stained with PE-conjugated anti-caspase3 antibodies and subjected to FACS analyses. The data were obtained from only GFP-positive cells and represent two independent experiments carried out in duplicate IG20 enhances TRAIL-induced apoptosis M Ramaswamy et al to TRAIL-induced apoptosis (Figure 4) . Since both the CrmA and the DN-FADD rendered HeLa IG20 cells highly resistant to TRAIL-induced apoptosis, we inferred that IG20 enhances TRAIL-induced apoptosis primarily through caspase-8.
IG20 colocalizes with DR4 in HeLa cells
Caspase-8 and FADD are two signaling molecules that are proximal to DR4/DR5 and are required for TRAILinduced apoptosis (Bodmer et al., 2000; Kischkel et al., 2000; Sprick et al., 2000) . IG20 does not interact directly with FADD (Schievella et al., 1997) , but requires intact FADD and caspase-8 to mediate its effects. In addition, IG20 has a 70 amino-acid death domain homology region (DDHR) in the C-terminal. Therefore, we wondered whether the observed increase in apoptosis in HeLa IG20 cells could result from protein interaction between IG20 and the DRs. To address this, we initially carried out colocalization studies using IG20-YFP and DR4-CFP constructs. These proteins were expressed in 293T cells and immunoblotted using a GFP antibody to check for spontaneous cleavage of the fluorescent tags. Both constructs expressed expected size fusion proteins with no detectable cleavage of either YFP or CFP (data not shown). Overexpression of death receptors in vivo results in spontaneous oligomerization resulting in apoptosis of cells. Similarly, the DR4-CFP construct caused apoptosis when overexpressed in HeLa cells. To minimize spontaneous cell death due to receptor overexpression, we optimized levels of expression by lowering its ratio with respect to IG20-YFP in cotransfection experiments. As seen in Figure 5a and b, both fusion proteins were simultaneously expressed in the cotransfected HeLa cells. The expression of DR4-CFP is restricted mostly to the membrane, but also found in the cytoplasm as indicated by a series of Z-stack pictures captured in the CCD camera (data not shown). Figure 5c is an overlay image, which demonstrates that the two proteins are colocalized.
DR4 and DR5 interact with full length and the middle fragment of IG20
To more directly demonstrate that IG20 can interact with DR4 and DR5 and to further extend the colocalization data, we cotransfected 293T cells with the IG20-His and a DR4-Flag or a DR5-Myc construct. Immunoprecipitation of lysates from transiently transfected 293T cells was carried out using either a polylconal IG20 peptide antibody or a Flag-specific antibody. As seen in Figure 6a , immunoprecipitate (IP) using an anti-IG20 peptide antibody from lysates of IG20-His and DR4-Flag cotransfected cells (Lane 1), but not of cells transfected with DR4-Flag alone (Lane 2), showed association of DR4-Flag protein with IG20.
In order to further confirm these results, we used a GFP fusion construct of DIG20, that contains all the splice sites observed to date at the N-terminal end and the death domain homology region (DDHR) at the Cterminal end (Figure 6e ). In this experiment, we did the reverse-IP using the flag antibody ( Figure 6b ). As seen in Figure 6b , the 125 kDa DIG20-GFP was immunoprecipitated using the Flag-specific antibody only from lysates of cells cotransfected with DIG20-GFP and DR4-Flag (Lane 1), but not from DIG20-transfected cells alone (Lane 2).
To confirm whether IG20 could interact with DR5, we cotransfected cells with DR5-Myc and IG20-His constructs ( Figure 6c ) and used the cell lysate to carry out immunoprecipitation. Antibody to IG20 coprecipitated DR5-Myc-(Lane 1) and Myc-specific antibody To reconfirm these interactions, we used the DIG20-GFP construct cotransfected with a DR5-CFP construct (Figure 6d ). Immunoprecipitation of lysates from cells cotransfected with DIG20-GFP and DR5-CFP with IG20 antibody (Lane 2) showed the presence of both proteins confirming that DIG20 interacts with DR5. Together these results showed that IG20 interacts with both DR4 and DR5 and the IG20 domain that interacts with the DRs lies within the 748 amino-acid residues that constitute DIG20.
Recruitment of caspase-8 and FADD to the DR4 and DR5 DISC is increased in HeLa IG20 cells TRAIL-induced signaling through DR4 and DR5 results in the formation of DISC that contains FADD and caspase-8, which are the main proximal initiators of apoptosis. Moreover, IG20 interacts with the DR4 and DR5. Therefore, one possible mechanism by which IG20 can render cells more susceptible to apoptosis is through enhanced TRAIL DISC formation. The TRAIL DISC was immunoprecipitated from lysates (equalized for protein) of control or HeLa IG20 cells using anti-DR4 and anti-DR5 antibodies after TRAIL treatment for the indicated periods of time. As seen in Figure 7a , there is an increased recruitment of procaspase-8 into the DISC from HeLa IG20 cells relative to control cells. Furthermore, increased cleavage of procaspase-8 into its active p43/41 fragments was also evident. This effect was time dependent and correlated well with the previous results, which showed an increase in the processed p10 form of caspase-8 in HeLa-IG20 cells when compared to control cells (Figure 3c) . A similar increase was observed in the DR5 DISC from HeLa IG20 cells (Figure 7b ). We observed increased FADD recruitment to the DISC associated with both DR4 and DR5 in HeLa IG20 cells relative to control cells. Although similar amounts of DR5 were immunoprecipitated from both cell types, there was considerable increase in the DISC components from HeLa-IG20 cells (Figure 7b ). In fact, the level of immunoprecipitated DR4 is lower in HeLa IG20 samples compared to control cells, and yet it showed higher levels of caspase-8 recruitment (Figure 7a ).
Discussion
The current study shows that IG20 can render cells more susceptible to TRAIL-induced apoptosis primarily by increasing the recruitment of FADD and caspase-8 to the DISC that results in enhanced activation of caspase-8 and -3. These observations are further substantiated by the results obtained using caspase inhibitors and DN-FADD and support the notion that IG20 is modulating the TRAIL-induced apoptosis by increasing DISC formation. Apoptosis is characterized by universal activation of caspases (reviewed in Thornberry and Lazebnik, 1998). Our results showed that IG20 could substantially increase TRAIL-induced caspase activation relative to the levels seen in control cells. This was further confirmed by increased mitochondrial depolarization and increased chromatin condensation, which are hallmarks of apoptosis (Figure 1) (Kerr et al., 1972) .
TRAIL can bind to five distinct receptors -DR4 (TRAILR-1), DR5 (TRAILR-2), Decoy Receptor 1 (DcR1, TRAILR-3, LIT or TRID), Decoy Receptor 2 (DcR2, TRAILR-4, TRUNDD) and Osteoprotegerin (OPG) (reviewed in Ashkenazi and Dixit, 1999) . Among these receptors, only DR4 and DR5 contain cytoplasmic death domains (DD) and are able to transduce apoptotic signals upon TRAIL binding. Although TRAIL can ligate both the DcR1 and DcR2, they are unable to transduce apoptotic signals since their cytoplasmic tails lack a DD or have a partial DD (Degli-Esposti et al., 1997; Pan et al., 1997 Pan et al., , 1998 . Earlier, the ability of TRAIL to selectively kill cancer cells was attributed to the dominant-negative effects of the decoy receptors expressed on normal, but not on cancer cells, that can compete for TRAIL binding (Sheridan et al., 1997) . Recent studies showed that expression of DR4 determined the levels of TRAIL susceptibility . Our studies, however, showed that cell surface expression and turnover of the DRs and DcRs were at comparable levels in both HeLa IG20 and control cells (Figure 2a, c) . Therefore, the enhanced susceptibility of HeLa IG20 cells could not be accounted for by the differential surface expression or turnover of DRs or DcRs. Another recent study (Lim and Chow, 2002) claimed enhanced apoptosis and transcriptional upregulation of TRAIL in jurkat cells due to knockdown of DENN using antisense DENN oligonucleotides. However, since the oligonucleotides used could bind to all splice variants, and was not specific to DENN, the upregulation of TRAIL expression was most likely due to knock-down of all IG20 splice variants. Nevertheless, this suggested that IG20 or its splice variants could be involved in the regulation of TRAIL gene expression. Our results (Figure 2b) , however, showed that expression of exogenous IG20 had no discernible effect on the transcription of TRAIL or the TNFR1 in HeLa cells.
A considerable increase in not only caspase-8 and -10, but also in caspase-9, which is primarily activated by the mitochondrial pathway, was seen in HeLa IG20 cells (Figure 3a, b) . In this study, we used flourochromeconjugated caspase-specific peptide inhibitors to detect activation of specific caspases. Caspase-8 activation was corroborated, by detecting its cleaved p10 fragment, using a specific antibody (Figure 3c ). These results are not surprising since downstream effector caspases can be activated either by caspase-8 directly (Type I response) or indirectly through Bid cleavage, resulting in the activation of caspase-9 through the mitochondrial pathway (Type II response), or both (Ozoren and ElDeiry, 2002) . Activation of the mitochondrial pathway, although first described in CD95-mediated signaling, is now implicated in TRAIL-induced apoptosis where the susceptibility of certain cancer cells to apoptosis is dependent upon the presence of smac/DIABLO and Bax (Deng et al., 2002; LeBlanc et al., 2002) . Similarly, caspase-10 can participate along with caspase-8 in DR4 and DR5 signaling pathways (Kischkel et al., 2001) . One of the known consequences of activation of initiator caspases, like caspase-8, -10 and -9, is that they all can activate the downstream effector caspase-3. As expected, an increase in caspase-3 was evident in HeLa IG20 cells (Figure 3d, e) .
Owing to its broad effect, p35 can protect against death receptor as well as stress-induced mitochondriamediated apoptosis (Beidler et al., 1995; Bump et al., 1995) . Expression of p35 in HeLa cells with and without IG20 totally blocked TRAIL-induced apoptosis, most likely by inhibiting relevant caspases. On the other hand, Figure 7 Enhanced recruitment of caspase-8 into the DISC of HeLa IG20 cells. HeLa IG20 and control cells (1 Â 10 7 ) were collected and treated with 1 mg/ml of TRAIL for the indicated duration. Lysates from treated as well as untreated cells were normalized for protein content and the DISC was precipitated using a DR4 (a) or a DR5 (b) -specific antibody. The immunoprecipitated samples were then immunoblotted using antibodies specific for caspase-8, FADD, DR4 or DR5. All blots were developed with ECL and exposed to the film for the same duration
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CrmA can protect cells from undergoing TNF-a-and CD95 ligand-induced apoptosis by primarily inhibiting caspase-8 (Ray et al., 1992; Zhou et al., 1997) . Although HeLa IG20 cells showed enhanced activation of caspase-8, -9 and -10, CrmA inhibited TRAIL-induced apoptosis almost completely (Figure 4) and strongly supported the notion that IG20 can enhance TRAIL-induced apoptosis primarily through enhanced activation of caspase-8. Earlier we had shown that IG20 proapoptotic splice variant could enhance TNF-a-induced apoptosis through increased activation of caspase-8 (Al-Zoubi et al., 2001 ). Now it is apparent that IG20 has a similar effect on TRAIL-induced caspase-8 activation. Collectively, these studies show that IG20, like FADD and caspase-8, is involved in the signaling pathway of more than one member of the TNF superfamily. FADD is necessary for caspase-8 recruitment to the TRAIL DISC (Kuang et al., 2000) . Therefore, we used a DN-FADD to prevent FADD, and subsequent caspase-8 recruitment and showed that it can suppress TRAILinduced apoptosis in HeLa-IG20 cells. An earlier report has shown that FADD does not directly bind to the DRs in a yeast two-hybrid assay (Miyazaki and Reed, 2001) ; therefore, it is not clear as to how FADD is recruited to the TRAIL DISC. Similarly, FADD cannot directly interact with IG20 (Schievella et al., 1997) , and yet we observed a total abrogation of apoptosis in DN-FADD-transfected cells (Figure 4 ). These observations raised the possibility that IG20 could be acting upstream of FADD perhaps through direct interactions with the DRs.
Results from cotransfection of fluorescently tagged DR4 and IG20 showed colocalization of these two proteins in HeLa cells. Moreover, coimmunoprecipitation of death receptors and IG20 showed that they interact with each other. Interaction of DRs with the DIG20, which consists of 748 AA including the DDHR and the splice regions, but lacks the N-terminal and the C-terminal regions of IG20 (Figure 6 ), indicated that it might be sufficient to mediate IG20 effects. However, further detailed studies are required to fully delineate various functional domain(s), including DR interacting domains of IG20. Whether other splice variants of IG20 can also affect TRAIL-mediated apoptosis and interact with DRs is currently under investigation.
CD95L-and TRAIL-induced signaling results in DISC formation characterized by the recruitment of FADD and caspase-8 (Kischkel et al., 1995) . Subsequent to TRAIL treatment, there was not only an increased recruitment of FADD and caspase-8 to the DISC in HeLa IG20 cells but also an increase in cleaved caspase-8 (Figure 7) . Furthermore, a significant increase in FADD recruitment to the DISC was found earlier after TRAIL treatment in HeLa IG20 cells, relative to the levels seen in the control cells. We did not test for the levels or presence of caspase-10, since it has been shown that even though caspase-10 is recruited to DR4 and DR5, it does not functionally substitute caspase-8 (Sprick et al., 2002) . Moreover, near complete inhibition of apoptosis in the presence of CrmA also indicated that caspase-8 was sufficient for TRAIL-induced apoptosis of both HeLa IG20 and control cells.
A recent study showed that treatment of cells with an antisense oligonucleotide that could suppress expression of all IG20 splice variants, identified to date, resulted in enhanced apoptosis and reduced cell proliferation (Lim and Chow, 2002; Lim et al., 2004) . In this context, it is interesting to note that cells that lack expression of endogenous IG20 (e.g. PA-1 ovarian carcinoma cells), but express DENN-SV at higher levels, are highly proliferative and resistant to TRAIL-induced apoptosis. However, upon expression of exogenous IG20, these cells become more susceptible to TRAIL-induced apoptosis and show reduced proliferation (Efimova et al., 2004) . Collectively, these studies indicate that IG20 gene, through alternative splicing, can play an important role in the regulation of cell proliferation and death.
How interactions between IG20 and DRs bring about enhanced recruitment of FADD and caspase to the DISC is currently under investigation. IG20 consists of two putative protein interacting domains namely, the DDHR and the N-terminal leucine zipper. These regions could allow homotypic association of IG20 with itself, or heterotypic interactions with other adaptor proteins resulting in increased DISC formation. Alternatively, it is intriguing to note that IG20 is homologous to the rat Rab3 guanine nucleotide exchange protein (Rab3-GEP) (Wada et al., 1997; Brown and Howe, 1998) . This protein regulates the activation of Rab3 GTPases, required for vesicle trafficking (Tanaka et al., 2001) , by catalysing the guanine nucleotide exchange activity (Takai et al., 1996) and this activity is dependent on the DDHR (Coppola et al., 2002) . However, whether the GEP function of IG20 plays any role in regulating TRAIL-induced apoptosis also remains to be elucidated.
Although selective killing of cancer cells by TRAIL has significant implications for cancer therapy, recent studies show that most cancer cells are only marginally sensitive to TRAIL-induced apoptosis (Ravi et al., 2001; Sarker et al., 2002) . Combining TRAIL with chemotherapeutic drugs has proven effective in killing some but not all tumor cell lines (Walczak et al., 1999; Sarker et al., 2002) . A clearer understanding of the underlying mechanisms of IG20-mediated effects could lead to the development of novel methods to enhance the efficacy of TRAIL treatment in cancer.
In summary, the current study further defines IG20 as a proapoptotic protein that can interact with DR4 and DR5 and significantly enhance TRAIL induced apoptosis by facilitating DISC formation resulting in increased recruitment of FADD and caspase-8.
Materials and methods
Construction of plasmids
A cDNA encoding IG20 proapoptotic splice variant (GeneBank Accession Code-AF440101, from here on termed IG20) was cloned in-frame into pcDNA3. 1/NT/GFP/TOPO vector (Invitrogen, Carlsbad, CA, USA) using the TA cloning site from the previously described pBKRSV clone (Al-Zoubi et al., . The His-tagged IG20 construct has been described previously (Al-Zoubi et al., 2001) . IG20 was also subcloned into Bgl II and Apa I sites of the EYFP-C1 vector (Clontech, Palo Alto, CA, USA). The DIG20 construct was made by specific PCR amplification of a 748-residue fragment (amino acid 628-1376) from the full-length IG20. This PCR-amplified product was directly ligated into the TA cloning site of pcDNA3.1/NT/GFP/TOPO vector. The DR4-Flag construct, a gift from Vishva M Dixit (Genentech, South San Francisco, CA, USA), was used to subclone DR4 into the Bgl II and Eco RI sites of ECFP-N1 vector (Clontech). The DR5-Myc was a gift from WS El-Deiry (University of Pennsylvania, Philadelphia, PA, USA) and was used to clone the DR5 construct into the Bgl II and Eco RI sites of ECFP-N1 vector.
Cell lines
IG20 tagged with GFP and the pcDNA3.1/NT/GFP/TOPO. empty vector (10 mg each) were transfected into HeLa cells using the superfect reagent from Qiagen Inc. (Valencia, CA, USA). At 3 h post-transfection, cells were washed with 1 Â PBS and replenished with Dulbecco's modified Eagle's medium (Gibco Invitrogen Co., Carlsbad, CA, USA) with 10% fetal bovine serum, 2 mM L-glutamine and antibiotics (penicillin G-100 U/ml and streptomycin-100 mg/ml). All cell lines were cultured at 371C in a humidified atmosphere containing 5% CO 2 . Stably transfected cells of HeLa IG20 and Vector Control were established by culturing cells in growth medium containing G418 (400 mg/ml) for 3 weeks, with weekly change of the medium and expression was confirmed by immunoprecipitation of IG20-GFP protein (data not shown).
Antibodies and other reagents
The anti-IG20 peptide polyclonal antibody, raised against three different peptides from the N-terminal, middle and C-terminal region of IG20, has been previously described (Al-Zoubi et al., 2001) . Anti Caspase-8 antibody (C-15) was a gift from Marcus E Peter (Ben May Institute of Cancer Research, University of Chicago, Chicago, IL, USA). Anticaspase-8 monoclonal antibody 6B6 was purchased from Cell Signaling Technology Inc. 
Mitochondrial depolarization and chromatin condensation
A total of 2 Â 10 5 HeLa IG20 and Vector control cells were plated into a 12-well culture dish and allowed to grow for 48 h. Duplicate wells were left untreated or treated with 10 ng/ml of TNF-a and 10 mg/ml of cycloheximide. Equal numbers of cells were left untreated or treated with recombinant TRAIL at 100 ng/ml and both treatments lasted for 5 h. Cells were assessed for loss of mitochondrial membrane potential by staining with tetramethylrhodamine ethyl ester (100 nm, Molecular Probes, Eugene, OR, USA) for 10 min, washed once with ice-cold PBS, collected and subjected to FACS analysis. Cells from parallel samples were stained with 1 mg/ml Hoechst 33342 (Sigma-Aldrich Corp.) for 10 min and viewed under a Diaphot 200 inverted microscope with an epifluorescence attachment to analyse chromatin condensation.
Caspase activation
To assess the general activation of caspases, cells were stained with FITC-tagged caspase inhibitor Val-Ala-Asp-flouromethyl ketone (Promega, Madison, WI, USA) for 10 min at 371C, washed and analysed by FACS for percentage of FITCpositive cells. The initiator caspases were analysed by using carboxyflourescein-labeled peptide fluoromethylketone inhibitors (FAM-peptide-FMK) directed against active caspase-8, -9 and -10 (APO LOGIX caspase detection kit, Cell Tech Inc., Minneapolis, MN, USA). For testing levels of active caspase-3, cells were fixed and permeabilized using cytofix/cytoperm solution (BD Pharmingen, San Diego, CA, USA) for 30 min at 41C. Cells were washed with Perm/wash buffer (BD Pharmingen) and stained for 1 h in the dark at room temperature with 10 ml per sample of active-anti-caspase-3 PE-conjugated antibody. Cells were collected, washed once, resuspended in Perm/ wash buffer and analysed by FACS for PE-positive population. For detecting the caspase-8 cleaved fragment, 1 Â 10 7 of vector and IG20-transfected HeLa cells were treated with 100 ng/ml of TRAIL for 1 or 3 h, lysed with RIPA lysis buffer and normalized for protein concentration. The proteins were separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE), transferred and probed for the p10 cleaved caspase-8 fragment using the 6B6 antibody.
Cell surface expression levels of TRAIL receptor
A total of 5 Â 10 5 HeLa control and IG20 cells were collected in enzyme-free solution, washed once with PBS containing 0.5% BSA and allowed to stand in the same buffer for 10 min at 41C. We used PE-conjugated anti-DR4 (DJR1 clone), anti-DR5 (DJR2-4 clone), anti-DcR1 (DJR3 clone) and anti-DcR2 (DJR4-1 clone) antibodies purchased from eBiosciences (San Diego, CA, USA). Each sample was incubated with 20 ml of specific as well as control mouse IgG antibody per sample for 30 min at 41C. The cells were then washed with 1 Â PBS and analysed by FACS using a FACScan (Becton Dickinson, San Jose, CA, USA).
RT-PCR
A total of 1 Â 10 6 HeLa IG20 and vector control cells were collected and poly-A þ cytoplasmic mRNA was extracted using mMACS mRNA Isolation Kit (Miltenyi Biotec Inc., Auburn, CA, USA) according to the manufacturer's protocol. The RT-PCR was carried out using 500 ng mRNA from each sample and employing the SuperScript-One-Step RT-PCR System (Life Technologies, Rockville, MD, USA). The cDNAs were synthesized by first incubating at 501C for 30 min followed by incubation at 941C for 2 min. Subsequently, 30 cycles of PCR was carried out with denaturation at 941C for 30 s, annealing at 551C for 30 s, and extension at 721C for 1 min, followed by a final incubation at 721C for 7 min. The primers used for amplifying TRAIL were (forward: 5 0 -CAACTCCGTCAGCTCGTTAGAAAG-3 0 , reverse: 5 0 -TTA GACCAACAACTATTTCTAGCACT-3 0 ), for TNFR1 (forward: 5 0 -GTGCTGTTGCCCCTGGTCAT-3 0 , reverse: 5 0 -TT CTGCAGCTCCAGCCG-3 0 ) and GAPDH (forward: 5 0 -TG AAGGTCGGAGTCAACGGATTTGGT-3 0 , reverse: 5 0 -CA TGTGGGCCATGAGGTCCACCAC-3 0 ) and are expected to give rise to 452, 542 and 983 bp products respectively. The samples were run on a 5% TBE PAGE for visualization.
Brefeldin A treatment
Equal number of control and IG20 HeLa cells were treated with brefeldin A (1 mg/ml, Sigma-Aldrich Corp.) for the indicated time periods and analysed by FACS after staining with anti-DR5 antibody (DJR2-4 clone).
Transfection with dominant-negative FADD, CrmA and p35 constructs Control vector and IG20 stably transfected HeLa cells were plated at 5 Â 10 5 overnight and the dominant-negative FADD, Crm A and p35 constructs were cotransfected (2 mg each) with farnesylated EGFP at a ratio of 1 : 5. Equal numbers of wells were cotransfected with an appropriate control vector along with EGFP-F at the same ratio. The transfected cells were left untreated or treated with the TRAIL, or with TNF-a and cycloheximide, for 5 h and cells were collected and stained for active caspase-3 (anti caspase-3 antibody) and subjected to FACS analysis to detect active caspase-3 staining in GFPpositive cells.
Colocalization studies
In total, 2 Â 10 4 HeLa cells plated on chamber slides were cotransfected with the DR4-CFP and IG20-YFP constructs in a ratio of 1 : 5 (total 5 mg of DNA). At 12 h, the cells were treated with 10 mM of Z-VAD. After 24 h of transfection, the cells were fixed in 4% formaldehyde fixative solution, washed with PBS and mounted with coverslips using the Vectashieldmounting medium (Vector Labs, Burlingame, CA, USA). Slides were then imaged on an Olympus 1 Â 70 epifluorescence microscope using the slide book program (Intelligent-Imaging Innovations, Denver, CO, USA) under a Â 100 oil-immersion objective. The individual channels used were captured in a Z-series on a CCD digital camera.
Coimmunoprecipitation
Either IG20-His or DIG20-GFP were cotransfected with DR4-Flag in a ratio of 2 : 1 (a total of 15 mg of DNA) into 0.5 Â 10 6 293T cells using calcium phosphate transfection method. Cotransfections of IG20-His, DIG20-GFP were also carried out with DR5-Myc constructs. Cells were collected and lysed 24 h after transfection in lysis buffer (20 mM Tris/HCl, pH 7.5, 137 mM NaCl, 2 mM b-glycerophosphate, 2 mM EDTA, 1 mM Na 3 VO 4 , 2 mM sodium pyrophosphate, 2 mM phenylmethylsulfonyl fluoride (PMSF), protease inhibitors cocktail (Roche), 1% Triton X-100 and 10% glycerol) for half an hour on ice and then clarified by centrifugation at 12 000 r.p.m. for 30 min at 41C. Cell lysates were immunoprecipitated overnight with either 10 ml/ml of anti-IG20 peptide antibodies, 5 mg/ml of antiFlag M2 antibodies, 5 mg/ml of Myc antibody (Zymed, South San Francisco, CA, USA) or 5 mg/ml of DR5 (IMG 120). Protein A/G beads were added and samples were conjugated for 2 h after which beads were washed three times with lysis buffer and boiled in SDS lysis buffer. The eluates were then subjected to SDS-PAGE for subsequent immunoblot analysis.
Immunoprecipitation and DISC analysis
Control and IG20 HeLa cells (2 Â 10 7 ) were collected and left untreated or treated with TRAIL at a concentration of 1 mg/ml in a 371C water bath for 10 min or 30 min. At the end of the treatment, the cells were immediately washed with ice-cold 1 Â PBS and pelleted. The washed cells were then lysed with 1 ml of lysis buffer (30 mM Tris/HCl, pH 7.5, 150 mM NaCl, 2 mM EDTA, 1 mM phenylmethylsulfonyl fluoride (PMSF), protease inhibitors cocktail (Roche, Mannheim, Germany), 1% Triton X-100 and 10% glycerol) on ice for 30 min and clarified by centrifugation at 12 000 r.p.m. for 30 min at 41C. The supernatants, normalized for protein concentration, were immunoprecipitated with 2 mg of H-130 DR-4/DR-5 antibody on a roto shaker at 41C for 4 h followed by the addition of 25 ml of 50% slurry of Protein A/G (Amersham, Piscataway, NJ, USA) beads for another 2 h. The beads were washed thrice with the lysis buffer and the complex was separated from the beads by boiling it in the SDS lysis buffer for 5 min. The eluate was subjected to SDS-PAGE using a 12% gel for subsequent Immunoblot analysis.
Western blot analysis
The membranes were blocked with 5% milk (for coimmunoprecipitation assays) or 2% BSA (for DISC analysis) in PBS with 0.5% Tween 20 for 1 h, and the primary and secondary antibodies were incubated in PBST with 5% milk. The primary antibodies were used at concentrations of 1 mg/ml and the secondary antibodies at a concentration of 1 : 2000 to 1 : 10 000. All blots were developed using the ECL plus kit from Amersham following the manufacturer's protocol.
